Researchers repurpose pain meds to kill cancer cells
Researchers at the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy. In a recent study published in Oncogene, the researchers successfully translated DrugPredict results into the laboratory, and showed common pain medications—like aspirin—can kill patient-derived epithelial ovarian cancer cells.
In the new study, DrugPredict suggested non-steroidal anti-inflammatory drugs, also known as NSAIDs, could have applications for epithelial ovarian cancer. The researchers exposed patient-derived epithelial ovarian cancer cells growing in their laboratory to a specific NSAID, indomethacin, and confirmed the DrugPredict finding. Indomethacin killed both drug-resistant and drug-sensitive epithelial ovarian cancer cells. Interestingly, cisplatin-resistant epithelial ovarian cancer cells were most sensitive to indomethacin. When the researchers added chemotherapy drugs to the experiments, the cancer cells died even faster. The findings could represent the first step toward a new therapy regimen for epithelial ovarian cancer.
Epithelial ovarian cancer is the fifth leading cause of cancer deaths in women, killing approximately 14,000 women annually in the United States. Available therapies are only moderately successful, with more than 70 percent of women dying within five years of diagnosis. According to the authors, part of the challenge in developing new ovarian cancer drugs lies in escalating clinical trial costs and lengthy drug development timelines. Programs like DrugPredict could “reposition” FDA-approved medications for new indications—a more efficient strategy.
“Traditional drug discovery process takes an average of 14 years and billions of dollars of investment for a lead anti-cancer drug to make the transition from lab to clinic,” said study first author Anil Belur Nagaraj, PhD, research associate at Case Western Reserve University School of Medicine. “Drug re-positioning significantly shortens the long lag-phase in drug discovery and also reduces the associated cost.”
DrugPredict was developed by co-first author QuanQiu Wang of ThinTek, LLC, and co-senior author Rong Xu, PhD, associate professor of biomedical informatics in the department of population and quantitative health sciences at Case Western Reserve University School of Medicine. The program works by connecting computer-generated drug profiles—including mechanisms of action, clinical efficacy, and side effects— with information about how a molecule may interact with human proteins in specific diseases, such as ovarian cancer.
DrugPredict searches databases of FDA-approved drugs, chemicals, and other naturally occurring compounds. It finds compounds with characteristics related to a disease-fighting mechanism. These include observable characteristics—phenotypes—and genetic factors that may influence drug efficacy. Researchers can collaborate with Xu to input a disease into DrugPredict and receive an output list of drugs—or potential drugs—with molecular features that correlate with strategies to fight the disease.
“For any given disease, DrugPredict simultaneously performs both a target-based, and phenotypic screening of over half a million chemicals, all in just a few minutes,” Xu said.
In the Oncogene study, DrugPredict produced a prioritized list of 6,996 chemicals with potential to treat epithelial ovarian cancer. At the top of the list were 15 drugs already FDA-approved to treat the cancer, helping to validate the DrugPredict approach. Of other FDA-approved medications on the list, NSAIDs ranked significantly higher than other drug classes. The researchers combined the DrugPredict results with anecdotal evidence about NSAIDs and cancer before confirming DrugPredict results in their laboratory experiments.
The program could help identify safe alternatives for diseases—like epithelial ovarian cancer—that desperately require new treatment options. “The primary advantage of drug re-positioning over traditional drug development is that it starts from compounds with well-characterized pharmacology and safety profiles. This significantly reduces the risk of adverse effects and attrition in clinical trials,” Xu said.
“By combining my laboratory’s expertise in ovarian cancer biology and Dr. Xu’s expertise in bioinformatics, we were able to uncover a potentially novel drug approach to treat ovarian cancer,” said co-senior author Analisa DiFeo, PhD, the Norma C. and Albert I. Geller Designated Professor of Ovarian Cancer Research and assistant professor in the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine.
Said Nagaraj, “Currently there are no drugs targeting cancer stem cells being evaluated in ovarian cancer clinical trials. Our results provide a rationale to test NSAIDs like Indomethacin as a novel drug in ovarian cancer clinical trials.”
DiFeo is planning to test indomethacin’s ability to specifically target ovarian cancer stem cells in patient tumors in a phase 1 clinical trial. She will conduct the trial in collaboration with Steven Waggoner, MD, division chief of gynecologic oncology at University Hospitals Seidman Cancer Center and professor of obstetrics and gynecology at Case Western Reserve University School of Medicine.
Learn more: Computer Program Finds New Uses for Old Drugs
The Latest on: Predictive computer program
- Registering for DigiMax Crypto Trading App Now Openon November 23, 2020 at 5:39 am
DIGIMAX GLOBAL SOLUTIONS (the " Company " or " DigiMax ") (CSE:DIGI) is pleased to announce that in preparation for its December 1 trial launch of its Crypto Trading App, that it is now accepting User ...
- Digital analytics delivering cost-saving tire dataon November 22, 2020 at 11:14 pm
It stands out as a memorable showdown, a revealing “man vs. machine” moment in which a driver was one-upped by digital tire analytics. Micah Tindor, product manager, Connect Fleet, for Goodyear Tire & ...
- In silico drug discovery services market is likely to be worth USD 124 million by 2030, growing at an annualized rate of 15.6%, claims Roots Analysison November 21, 2020 at 2:12 pm
Roots Analysis has announced the addition of “In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and ...
- Industrial Analytics Market Report 2020 Share and Size, Expected CAGR, Analysis across the Region and Globe, Opportunities and Growth till 2023on November 20, 2020 at 7:42 pm
As per the Eurostat, the total value of the ICT sector in Europe, including the ICT manufacturing and ICT services, ...
- Future view: United Road bets on Uptake predictive maintenanceon November 20, 2020 at 1:21 pm
Mining big data to discover problems before they lead to breakdowns is comparatively new in commercial trucking. Heavy hauler United Road tested the service from Uptake. After a 400% return on ...
- Scientific Systems Company Builds Exclusive Team Comprising UAV with Search and Rescue Canineon November 20, 2020 at 1:43 am
Scientific Systems Company Builds Exclusive Team Comprising UAV with Search and Rescue Canine By CIOReview - SSCI's newly formed Teammate Aware Autonomy (TAA) system was employed with its ...
- Contact Centre Software Industry Analysis, 2020-2025 | Exclusive Report by Brand Essence Market Researchon November 19, 2020 at 3:52 pm
Global Contact Centre Software Market is valued at USD 14.98 Billion in 2018 and expected to reach USD 48.29 Billion by ...
- The 12 Coolest Machine-Learning Startups Of 2020on November 18, 2020 at 6:57 am
The 12 coolest machine-learning startups include companies that are developing leading-edge technology for building machine-learning models and collecting and managing the vast amounts of data needed ...
- Dragonfly AI raises £625k ($1m) in funding round to continue market lead in predictive analyticson November 17, 2020 at 1:21 am
British predictive analytics platform, DragonflyAI, is delighted to announce today the completion of a £625,000 ($1m) seed funding round. Downing Ventures is the lead investor in the round which ...
- HUAWEI CLOUD Named a Leader in Predictive Analytics and Machine Learningon November 16, 2020 at 6:26 pm
HUAWEI CLOUD was listed in the Leaders segment based on its scores in current offering and strategy, according to The Forrester Wave™: Predictive Analytics and Machine Learning in China, Q4 2020 ...
via Google News and Bing News